UNSPSC 51282927: Lomefloxacin

This classification denotes a quinolone antibiotic with the molecular formula C17H19F2N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L6BR2WJD8V, chemically known as 1,4-dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid but generally known as lomefloxacin, which bears US NIH Compound Identifier 3948. European Medicines Agency schedules Lomefloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08561MIG.

UNSPSC 51282927 Lomefloxacin, a Commodity code, shows minimal recent activity aligned with its nominal scope; state and local procurement under this code appears concentrated on generalized pharmaceutical and medical supply procurement rather than lomefloxacin specifically. The recent opportunities tagged to this code reflect broader health system purchasing: medical and first aid supplies for first responders, naloxone and drug deactivation systems for community health, generic multi-source pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription program design. None of these solicitations explicitly name lomefloxacin as a line item or primary deliverable, suggesting either mis-coding of opportunities in source systems or a mismatch between the code's pharmaceutical-specificity and actual procurement practice. State and local buyers using this code appear to include county health departments, city fire and rescue divisions, state health agencies, and cooperative purchasing alliances serving multi-state and multi-jurisdictional networks.

Recent activity spans Florida, Texas, Minnesota, and Oregon through cooperative arrangements. The City of Tampa issued an IFB for medical and first aid supplies ($700,000 estimated, due March 13, 2026) designated for small local business enterprises; Seminole County, Florida posted an IFB for naloxone and drug deactivation systems (1,900 units naloxone, 800 deactivation systems annually, due July 26, 2023) through competitive bidding; the Texas Health and Human Services Commission issued an RFI (due April 3, 2026) exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers. The code shows no apparent set-aside concentration or standout repeat buyers in recent postings.